Epstein-Barr virus antigen-derived peptide-MHC complex (EBV pMHC) (EBV pMHC)

Epstein-Barr virus (EBV) antigen-derived peptides presented on Major Histocompatibility Complex (MHC) molecules are the primary targets for cellular immune surveillance against EBV-infected cells. These complexes consist of short viral peptide fragments, derived from latent proteins such as EBNA1, LMP1, and LMP2, which are processed and loaded onto MHC Class I or Class II molecules for presentation on the cell surface (Taylor et al., 2015). In the context of EBV-associated malignancies, such as nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (PTLD), these pMHC complexes serve as highly specific tumor-associated antigens (Bollard & Heslop, 2016). Therapeutic interventions, most notably adoptive T-cell therapies like Tabelecleucel, utilize cytotoxic T-lymphocytes (CTLs) or engineered T-cell receptors (TCRs) to recognize these specific pMHC targets and induce apoptosis in the target cells (Prock et al., 2023). The efficacy of these treatments is often dependent on the specific HLA allele of the patient, as the peptide must fit the specific binding groove of the MHC molecule. Challenges in targeting these complexes include viral mechanisms of immune evasion, such as the downregulation of MHC expression, and the potential for off-target cross-reactivity with self-peptides (Long et al., 2011).

Other names

EBV peptide-HLA complexEBV-specific pMHCEpstein-Barr virus epitope-MHC complexEBV-derived antigen-MHC complexEBV-specific peptide-MHC complex

Recognition of viral peptide-MHC complexes by T-cell receptors (TCRs) on cytotoxic T-lymphocytes, triggering the release of perforins and granzymes to induce apoptosis in EBV-infected or malignant cells (Bollard & Heslop, 2016).